Long-Term Effectiveness and Safety of Dexmethylphenidate Extended-Release Capsules in Adult ADHD

被引：42

作者：

Adler, Lenard A. ^{[1
]}

Spencer, Thomas ^{[2
,3
]}

McGough, James J. ^{[4
,5
]}

Jiang, Hai

Muniz, Rafael ^{[6
]}

机构：

[1] New York VA Harbor Healthcare System, New York, NY USA

[2] Harvard Univ, Sch Med, Cambridge, MA 02138 USA

[3] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA

[4] Univ Calif Los Angeles, Div Child & Adolescent Psychiat, Los Angeles, CA 90024 USA

[5] Univ Calif Los Angeles, Program Attent Deficit Hyperact Disorders, Los Angeles, CA 90024 USA

[6] Novartis Pharmaceut, USCD & MA, E Hanover, NJ USA

来源：

JOURNAL OF ATTENTION DISORDERS | 2009年 / 12卷 / 05期

关键词：

adult ADHD; d-MPH-ER; long-term effectiveness; long-term safety; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; DL-THREO-METHYLPHENIDATE; DOUBLE-BLIND; D; L-THREO-METHYLPHENIDATE HYDROCHLORIDE; ENANTIOSELECTIVE PHARMACOKINETICS; LABORATORY SCHOOL; BABOON BRAIN; CHILDREN; PHARMACODYNAMICS;

D O I：

10.1177/1087054708320397

中图分类号：

B844 [发展心理学（人类心理学）];

学科分类号：

040202 ;

摘要：

Objective: This study evaluates dexmethylphenidate extended release (d-MPH-ER) in adults with ADHD. Method: Following a 5-week, randomized, controlled, fixed-dose study of d-MPH-ER 20 to 40 mg/d, 170 adults entered a 6-month open-label extension (OLE) to assess long-term safety, with flexible dosing of 20 to 40 mg/d. Exploratory effectiveness outcomes included change from Week 5 on ADHD Rating Scale (ADHD-RS) and proportion of responders on Clinical Global Impressions-Improvement (CGI-I) scale. Results: 103 patients completed OLE, and effectiveness was evaluable in 102 patients. d-MPH-ER was well tolerated; the most common adverse events (>15%) were headache, insomnia, and decreased appetite. Mean improvements in ADHD-RS score were -10.2 for patients switched from placebo to d-MPH-ER (n = 20) and -8.4 for those maintained on d-MPH-ER (n = 82). Respective CGI-I responder rates were 95.0% and 95.1%. Conclusion: Once-daily d-MPH-ER 20 to 40 mg is safe and effective for long-term treatment of adult ADHD. (J. of Att. Dis. 2009; 12(5) 449-459)

引用

页码：449 / 459

页数：11

共 23 条

[1] Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder [J].

Adler, L ;

Cohen, J .

PSYCHIATRIC CLINICS OF NORTH AMERICA, 2004, 27 (02) :187-+

[2]

[Anonymous], 2000, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425787

[3]

BIEDERMAN J, 2004, ANN M AM PSYCH ASS N

[4] Chiral drugs: Comparison of the pharmacokinetics of [C-11]d-threo and I-threo-methylphenidate in the human and baboon brain [J].

Ding, YS ;

Fowler, JS ;

Volkow, ND ;

Dewey, SL ;

Wang, GJ ;

Logan, J ;

Gatley, SJ ;

Pappas, N .

PSYCHOPHARMACOLOGY, 1997, 131 (01) :71-78

[5]

DING YS, 1995, J NUCL MED, V36, P2298

[6]

DuPaul GJ., 1998, ADHD 4 RATING SCALE

[7]

Guy W., 1976, ECDEU Assessment Manual for Psychopharmacology, V76, P217

[8] Dexmethylphenidate [J].

Keating, GM ;

Figgitt, DP .

DRUGS, 2002, 62 (13) :1899-1904

[9] The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers [J].

Kessler, RC ;

Adler, L ;

Ames, M ;

Barkley, RA ;

Birnbaum, H ;

Greenberg, P ;

Johnston, JA ;

Spencer, T ;

Üstün, TB .

JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE, 2005, 47 (06) :565-572

[10] The World Health Organization adult ADHD self-report scale (ASRS): a short screening scale for use in the general population [J].

Kessler, RC ;

Adler, L ;

Ames, M ;

Demler, O ;

Faraone, S ;

Hiripi, E ;

Howes, MJ ;

Jin, R ;

Secnik, K ;

Spencer, T ;

Ustun, TB ;

Walters, EE .

PSYCHOLOGICAL MEDICINE, 2005, 35 (02) :245-256

← 1 2 3 →